MedTrace Logo

Phase I/III Clinical Trial of Adsorbed Tetanus Vaccine

NCT07740733 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1240

Last updated 2026-08-03

No results posted yet for this study

Summary

The study aimed to evaluate the safety and immunogenicity of an adsorbed tetanus vaccine in healthy individuals between 18 and 43 years of age.

Conditions

  • Tetanus
  • Tetanus Vaccine

Interventions

BIOLOGICAL

Tetanus Toxoid (Adsorbed)

The study group's vaccines had been produced by Beijing Minhai Biotechnology Co., Ltd. Liquid formulation. 0.5 mL/vial.

BIOLOGICAL

Tetanus Toxoid (Adsorbed)

The manufacture of control group vaccines were Chengdu Olymvax Biopharmaceuticals Inc. Liquid formulation. 0.5 mL/vial.

Sponsors & Collaborators

  • Beijing Minhai Biotechnology Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
43 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-02-29
Primary Completion
2024-12-23
Completion
2024-12-23

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07740733 on ClinicalTrials.gov